CureVac-B (01167.HK) announced that at the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego, California in 2024, preliminary data from the phase one clinical trial of the BET inhibitor "JAB-8263" for treating myelofibrosis (MF) was presented.

The data indicated that "JAB-8263" has good tolerability, with a recommended dose of 0.3 mg (administered daily) for phase two. The preliminary efficacy data for "JAB-8263" as a monotherapy for myelofibrosis is encouraging, with most patients experiencing spleen shrinkage and a reduction in total symptom scores.

CureVac revealed that as of October 17 this year, 16 patients with intermediate/high-risk myelofibrosis have been enrolled in the study, with 13 patients having undergone at least one treatment efficacy evaluation. (js/w)

~